HUTCHMED Reports NMPA’s NDA Acceptance Under Priority Review for Sovleplenib to Treat wAIHA

Why It Matters

Sovleplenib could become the first approved therapy for wAIHA in China, addressing a high‑unmet‑need population that fails glucocorticoids. Its approval would also signal growing regulatory support for innovative hematology drugs in the region.

Key Takeaways

• Sovleplenib received NDA acceptance and priority review in China.
• Phase III trial met primary endpoint of durable hemoglobin response.
• Phase II showed 43.8% overall response vs 0% placebo at 8 weeks.
• Data published in The Lancet Haematology, boosting credibility.
• Potential first approved therapy for wAIHA in Chinese market.

Pulse Analysis

Warm‑antibody autoimmune hemolytic anemia remains a niche yet challenging hematologic disorder, with glucocorticoids as the first‑line therapy and limited options for patients who relapse or become refractory. The disease’s rarity has historically discouraged large‑scale drug development, but emerging oral agents targeting the JAK‑STAT pathway promise disease‑modifying effects. Sovleplenib, a selective JAK2 inhibitor, leverages this mechanism to curb the immune‑mediated destruction of red blood cells, positioning it as a potentially transformative option for clinicians and patients alike.

The pivotal Phase II/III program combined a randomized, placebo‑controlled Phase II segment with an open‑label Phase III extension. Phase II demonstrated a 43.8% overall response rate at eight weeks, starkly contrasting with a 0% response in the placebo arm, while the Phase III cohort achieved its primary endpoint of a durable hemoglobin increase within five to 24 weeks. Publication in The Lancet Haematology and upcoming presentation at the European Hematology Association conference underscore the robustness of the data, bolstering confidence among regulators and investors. The NMPA’s priority‑review status and breakthrough‑type designation further accelerate the timeline, reflecting China’s strategic push for innovative therapies.

If approved, sovleplenib would fill a critical therapeutic gap in the Chinese market, where wAIHA patients often face limited alternatives and prolonged hospitalizations. The drug’s oral administration simplifies chronic management compared with intravenous biologics, potentially expanding its appeal beyond China to global markets seeking novel hematology solutions. Analysts will watch post‑approval rollout, pricing strategy, and potential label expansions into related autoimmune hemolytic conditions, all of which could shape the competitive landscape and drive valuation for HUTCHMED and its partners.